Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Inclusion Criteria: 1. Healthy subject of either gender, 2. Age 12 to 18 months , 3. Consent form signed by both parent(s) or by the legal representative properly informed about the study, 4. Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card. Exclusion Criteria: 1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine, 2. Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster, 3. Any recent (≤30 days) exposure to measles, mumps or rubella, 4. Any recent (≤30 days) exposure to varicella or zoster involving: 5. Any recent (≤3 days) history of febrile illness 6. Any severe chronic disease, 7. Active untreated tuberculosis, 8. Known personal history of seizures, 9. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems, 10. Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, 11. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed 12. Any recent tuberculin test (≤7 days) or scheduled tuberculin test through visit 2, 13. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 2, 14. Any recent receipt of an inactivated or a live vaccine (≤30 days) or scheduled vaccination through visit 2